DrugPatentWatch Database Preview
CUBICIN RF Drug Profile
When do Cubicin Rf patents expire, and when can generic versions of Cubicin Rf launch?
Cubicin Rf is a drug marketed by Cubist Pharms Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has forty patent family members in twenty-seven countries.
The generic ingredient in CUBICIN RF is daptomycin. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the daptomycin profile page.
Summary for CUBICIN RF
| International Patents: | 40 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 12 |
| Clinical Trials: | 8 |
| Patent Applications: | 2 |
| Formulation / Manufacturing: | see details |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for CUBICIN RF |
| DailyMed Link: | CUBICIN RF at DailyMed |
Pharmacology for CUBICIN RF
| Drug Class | Lipopeptide Antibacterial |
Medical Subject Heading (MeSH) Categories for CUBICIN RF
Synonyms for CUBICIN RF
| 103060-53-3 |
| Cidecin |
| CS-1857 |
| Cubicin |
| Cubicin (TN) |
| D01080 |
| D4229 |
| Dapcin |
| Daptomicina |
| Daptomicina [Spanish] |
| DAPTOMYCIN |
| Daptomycin (JAN/USAN/INN) |
| Daptomycin [USAN:INN:BAN] |
| Daptomycin for injection |
| Daptomycine |
| Daptomycine [French] |
| Daptomycinum |
| Daptomycinum [Latin] |
| Deptomycin |
| EX-A1967 |
| HY-B0108 |
| LY 146032 |
| LY-146032 |
| LY146032 |
| MK-3009 |
| MolPort-046-033-485 |
| NWQ5N31VKK |
| SCHEMBL13491700 |
| UNII-NWQ5N31VKK |
US Patents and Regulatory Information for CUBICIN RF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CUBICIN RF
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | ➤ Sign Up |
International Patents for CUBICIN RF
Supplementary Protection Certificates for CUBICIN RF
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1115417 | 22/2006 | Austria | ➤ Sign Up | PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119 |
| 1115417 | CA 2006 00018 | Denmark | ➤ Sign Up | PRODUCT NAME: DAPTOMYCIN |
| 1115417 | SPC/GB06/024 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021. |
| 1115417 | SZ 22/2006 | Austria | ➤ Sign Up | PRODUCT NAME: DAPTOMYCIN |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
